Some 20 percent of the human genome is already patented . But a court ruled yesterday that one company does not have the rights to some of its patents on two genes, BRCA1 and BRCA2 , commonly tested for mutations to determine risk for developing breast and ovarian cancer. [More]
District court overturns patents on breast cancer genes
Did this article help you?
If you found this piece useful, please consider supporting our work with a small, one-time or monthly donation. Your contribution enables us to continue bringing you accurate, thought-provoking science and medical news that you can trust. Independent reporting takes time, effort, and resources, and your support makes it possible for us to keep exploring the stories that matter to you. Together, we can ensure that important discoveries and developments reach the people who need them most.